PLATINUM-RESISTANT OVARIAN CANCER
Clinical trials for PLATINUM-RESISTANT OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CANCER trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise against Hard-to-Treat cancers
Disease control TerminatedThis early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:39 UTC
-
New hope for tough ovarian cancer? trial tests targeted drug vs standard chemo
Disease control TerminatedThis study tested a new drug, luveltamab tazevibulin, against standard chemotherapy in 600 women with ovarian cancer that had stopped responding to platinum-based treatment. The drug targets a protein called FOLR1 found on cancer cells. The trial was terminated early, so results …
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:38 UTC
-
Cancer drug trial halted early: what we know
Disease control TerminatedThis study tested a drug called VLS-101 in people with advanced solid tumors, including breast, lung, stomach, pancreatic, and ovarian cancers that had stopped responding to other treatments. The goal was to see if the drug could shrink tumors. However, the trial was stopped earl…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Ovarian cancer combo trial halted: what we learned
Disease control TerminatedThis study tested a combination of two drugs, SON-1010 and atezolizumab, in people with advanced solid tumors and platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow cancer growth. The study was terminated early, so results are limite…
Matched conditions: PLATINUM-RESISTANT OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated May 01, 2026 15:56 UTC